GREY:ATBPF - Post by User
Comment by
MrMugsyon Jul 18, 2021 11:18am
186 Views
Post# 33566734
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:52 week low
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:52 week low Thanks Bagger!
For the first time in ATE's existance, I think we have everything in place to bring H2S awareness to those who matter most ... potential partners and potential suitors.
I was lucky - I learned about this company by following Knight's Goodman and his transactions with ATE. That's when I got in on the cheap. I did my DD to better understand what happened in the past and what the future looks like.
In all honesty, the future is coming together exactly as I had hoped, less the timing, but I've never been involved in a tiny biotech that lacked cash and one the barely survived a Phase 1 meltdown. I knew it wasn't going to be easy.
I also didn't expect COVID to be a future factor. Oh well ... survivors potentially become leaders if you can get through something like that (personal opinion).
Now we have the cash (more on the way) to stand firm during negotiations. We have a development plan (help from academia and Dalriada who represent the horses we need to move the plan forward). Finally, we can now move the family of drugs forward (352, 340+, Mesalamine+H2S). I see new molecules and IP extensions as critical but only possible when we fell into cash. So - should we have gone to market for cash at 40 cents ($4) and at 60 cents ($6)? You bet your right testical we should have.
Also, I rely on the 2014 Mesalamine+H2S study as a foreshadowing of what H2S can do for ulcer repair. I personally would be shocked if we don't see that characteristic of H2S come through during the P3 study ... but that's my own personal belief.
So I don't have the share price to sit still right now and the difference between share price and value is huge (in my opinion). That's why I started buying again below $4.
Just the way I see it.